mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults: A Meta-analysis

Jackson JL et al. – Botulinum toxin A compared with placebo was associated with a small to modest benefit for chronic daily headaches and chronic migraines but was not associated with fewer episodic migraine or chronic tension–type headaches per month.

Methods
  • A search of MEDLINE, EMBASE, bibliographies of published systematic reviews, and the Cochrane trial registries between 1966 and March 15, 2012.
  • Inclusion and exclusion criteria of each study were reviewed.
  • Headaches were categorized as episodic (<15 headaches per month) or chronic (≥15 headaches per month) migraine and episodic or chronic daily or tension headaches.
  • Randomized controlled trials comparing botulinum toxin A with placebo or other interventions for headaches among adults.
  • Data were ed and quality assessed independently by 2 reviewers.
  • Outcomes were pooled using a random–effects model.

Results
  • Pooled analyses suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1115 patients, –2.06 headaches per month; 95% CI, –3.56 to –0.56; 3 studies) and among patients with chronic migraine headaches (n = 1508, –2.30 headaches per month; 95% CI, –3.66 to –0.94; 5 studies).
  • There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine (n = 1838, 0.05 headaches per month; 95% CI, –0.26 to 0.36; 9 studies) or chronic tension–type headaches (n = 675, –1.43 headaches per month; 95% CI, –3.13 to 0.27; 7 studies).
  • In single trials, botulinum toxin A was not associated with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], –0.20; 95% CI, –0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, –0.36 to 0.76), or amitriptyline (SMD, 0.29; 95% CI, –0.17 to 0.76).
  • Botulinum toxin A was associated with fewer chronic tension–type headaches per month vs methylprednisolone injections (SMD, –2.5; 95% CI, –3.5 to –1.5).
  • Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck pain.
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close